Printer Friendly

ROBERTS PHARMACEUTICAL OBTAINS EXCLUSIVE CANADIAN RIGHTS TO MARKET UROLOGICAL DRUG

 ROBERTS PHARMACEUTICAL OBTAINS EXCLUSIVE CANADIAN RIGHTS
 TO MARKET UROLOGICAL DRUG
 EATONTOWN, N.J., April 8 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX), announced earlier today that effective July 1, it will become the exclusive Canadian distributor for RIMSO(R)- 50, a drug used to treat interstitial cystitis, a chronic inflammatory condition of the urinary bladder. RIMSO-50 will become the second urological drug marketed by Roberts in Canada, the other product being DUVOID(R), for treatment of urinary retention. Roberts obtained these rights to RIMSO-50 from Research Industries, Inc. of Salt Lake City, Utah. Research Industries markets and sells RIMSO-50 in the United States under its own label.
 "We are very pleased to add RIMSO-50 to our growing line of specialty pharmaceutical products," commented Robert A. Vukovich, Roberts president and CEO. "This product fits our strategy of focusing on niche markets and adds another very visible and unique therapeutic agent to our product line," he continued.
 RIMSO-50 is administered by direct bladder installation for relief of pain and inflammation associated with interstitial cystitis. The product is predominantly used by urologists as part of multi-modal approach to the treatment of this disorder.
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non- prescription pharmaceuticals in the United States and abroad.
 -0- 4/8/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceutical, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU:


SH-OS -- NY087 -- 6370 04/08/92 15:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 8, 1992
Words:281
Previous Article:MELROSE HAS IT AND SEAN YOUNG DOESN'T; FLASH SURVEY REVEALS WHAT HAS UH-HUH! AND WHAT DOESN'T
Next Article:NEVER-BEFORE-SEEN FOOTAGE OF ELVIS PRESLEY PERFORMANCES DISCOVERED IN MGM'S UNDERGROUND FILM VAULT


Related Articles
ROBERTS PHARMACEUTICAL OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO NEWLY APPROVED JOHNSON & JOHNSON ENDOCRINOLOGY DRUG
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES APPOINTMENT OF CHIEF OPERATING OFFICER
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES APPOINTMENT OF CHIEF OPERATING OFFICER
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES ACQUISITION OF SMITHKLINE BEECHAM RESPIRATORY DRUG
ROBERTS PHARMACEUTICAL CORPORATION ACQUIRES ETHMOZINE, A CURRENTLY MARKETED CARDIOVASCULAR DRUG FROM DU PONT MERCK
ROBERTS PHARMACEUTICAL CORPORATION LAUNCHES SUPPRELIN -- ROBERTS' FIRST NEW DRUG LAUNCH IN THE U.S.
ROBERTS PHARMACEUTICAL COMPLETES ACQUISITION OF ETHMOZINE FROM DU PONT MERCK
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES CANADIAN REGULATORY APPROVAL FOR AGRELIN(R) TREATMENT IND
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES AGREEMENT TO ACQUIRE MULTI-PRODUCT DRUG LINE FROM GLAXO CANADA
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES APPOINTMENT OF NEW GENERAL MANAGER OF CANADIAN SUBSIDIARY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters